MedTrace Logo

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

NCT05927844 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-07-03

No results posted yet for this study

Summary

This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in the treatment of locally advanced or metastatic esophageal squamous cell carcinoma.

Conditions

Interventions

DRUG

XH-30002 capsule

receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first

DRUG

Afatiinb tablet

receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Gen Lin, Ph.D · Fujian Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2025-06-30
Completion
2025-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05927844 on ClinicalTrials.gov